Mode
Text Size
Log in / Sign up
Phase 2 N=54 Randomized Double-blind Treatment

Brain Function and Structure in Cocaine Dependence

Cocaine Dependence

Enrolled (actual)
54
Serious AEs
0.0%
Results posted
Dec 2017
Primary outcome: Primary: Cocaine Use/Treatment Effectiveness Score (TES) — 6.6; 8.3; 29 percentage of negative urines

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Citalopram (Drug); Placebo (Drug)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Virginia Commonwealth University
Primary completion
Feb 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Cocaine Use/Treatment Effectiveness Score (TES)
6.6; 8.3; 29

Summary

The purpose of this study is to examine the role of brain MRI findings in predicting treatment outcomes among individuals with cocaine dependence.

Eligibility Criteria

Inclusion Criteria

  • Male and female subjects age 18 to 50 who meet current DSM-IV criteria for cocaine dependence who are seeking treatment.

Exclusion Criteria

  • Current DSM-IV diagnosis of any psychoactive substance dependence other than cocaine, marijuana, nicotine, or alcohol
  • Have a DSM-IV axis I psychiatric disorder or neurological disease or disorder requiring ongoing treatment and/or making study participation unsafe
  • Significant current suicidal or homicidal ideation
  • Medical conditions contraindicating citalopram pharmacotherapy (liver disease, seizure disorder, bleeding disorder, or prolonged QT interval on EKG)
  • Taking CNS active concomitant medications
  • Taking medications known to have significant drug interactions with the study medication
  • Having conditions of probation or parole requiring reports of drug use to officers of the court
  • Impending incarceration
  • Pregnant or breast feeding for female patients
  • Inability to read, write, or speak English
  • Having plans to leave the immediate geographical area within 3 months
  • Unwillingness or not competent to sign a written informed consent form
  • Individuals who have pacemakers, metal or electromechanical implants or metallic foreign bodies
  • Patients who are known to be HIV positive will not be included due to possible CNS effects of HIV.
  • Alcohol withdrawal symptoms or history of significant previous alcohol withdrawal symptoms.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02080832). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search